GoodRx (GDRX) Set to Announce Earnings on Thursday

GoodRx (NASDAQ:GDRX) is scheduled to post its quarterly earnings results before the market opens on Thursday, November 7th. Analysts expect GoodRx to post earnings of $0.09 per share for the quarter. GoodRx has set its FY 2024 guidance at EPS and its Q3 2024 guidance at EPS.Individual that wish to listen to the company’s earnings conference call can do so using this link.

GoodRx (NASDAQ:GDRX) last issued its quarterly earnings data on Thursday, August 8th. The company reported $0.08 earnings per share for the quarter, missing the consensus estimate of $0.09 by ($0.01). GoodRx had a positive return on equity of 3.63% and a negative net margin of 7.57%. The business had revenue of $200.60 million during the quarter, compared to analyst estimates of $200.47 million. During the same quarter last year, the firm earned $0.02 EPS. GoodRx’s revenue for the quarter was up 5.7% compared to the same quarter last year. On average, analysts expect GoodRx to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

GoodRx Price Performance

Shares of GoodRx stock opened at $6.38 on Thursday. GoodRx has a twelve month low of $4.14 and a twelve month high of $9.26. The company has a quick ratio of 7.32, a current ratio of 7.32 and a debt-to-equity ratio of 0.96. The company has a 50-day simple moving average of $7.22 and a two-hundred day simple moving average of $7.55. The stock has a market capitalization of $2.42 billion, a price-to-earnings ratio of -49.08, a price-to-earnings-growth ratio of 4.17 and a beta of 1.37.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on GDRX shares. Citigroup dropped their target price on shares of GoodRx from $11.00 to $10.00 and set a “buy” rating for the company in a research report on Friday, August 9th. Raymond James upgraded shares of GoodRx from an “outperform” rating to a “strong-buy” rating and set a $10.00 target price for the company in a research report on Friday, August 9th. UBS Group dropped their target price on shares of GoodRx from $9.00 to $8.50 and set a “neutral” rating for the company in a research report on Friday, August 9th. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $10.00 target price on shares of GoodRx in a research report on Friday, August 16th. One research analyst has rated the stock with a sell rating, four have issued a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $9.36.

Insider Buying and Selling at GoodRx

In other news, major shareholder Equity Vii L.P. Spectrum sold 10,677 shares of the company’s stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $7.86, for a total value of $83,921.22. The transaction was disclosed in a document filed with the SEC, which is available through this link. Corporate insiders own 4.17% of the company’s stock.

About GoodRx

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.